Loading...
•
Mar 31, 2020
Fulcrum Therapeutics Q1 2020 Earnings Report
Fulcrum Therapeutics reported financial results for the first quarter of 2020.
Key Takeaways
Fulcrum Therapeutics reported a net loss of $18.5 million for the first quarter of 2020, compared to a net loss of $36.8 million for the first quarter of 2019. As of March 31, 2020, cash, cash equivalents, and marketable securities were $81.2 million.
Amended ReDUX4, a Phase 2b trial of losmapimod, to accommodate COVID-19 impact; extended the trial from 24 to 48 weeks, adding a 36-week biopsy for those subjects unable to undergo their 16-week biopsy, and included an interim analysis on patients who completed their 16-week biopsy as planned in the original protocol.
ReDUX4 enrollment completed.
ReDUX4 open label extension initiated.
Data from interim analysis expected in the third quarter of 2020.
Fulcrum Therapeutics
Fulcrum Therapeutics
Forward Guidance
Based on its current plans, the Company expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the third quarter of 2021.